Trial Profile
A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- 15 Nov 2011 Planned end date changed from 1 Sep 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 15 Nov 2011 Planned end date changed from 1 Sep 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 15 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.